closure integrity, impurities, charge variants, oxidation, endotoxin, particulates and biological activity. Results A total of 132 syringes underwent three freeze-thaw cycles, exposing each syringe for a total of 144 hours to 30°C and 144 hours to À5°C. Following exposure, 66 syringes were used for the analysis and 66 were retained. The effects of this thermal cycling on the critical quality attributes of SB5 from baseline is shown in table 1. Conclusion and relevance SB5 was stable in the immediate pack when exposed to multiple freeze-thaw cycles. These results may help hospital pharmacists assess the impact of temperature excursions during shipment or storage on product quality of SB5.

Conclusion and relevance Considering the positive results obtained so far, the study of HIPEC with CRS in peritoneal carcinoma continues, to evaluate its effectiveness. The role of the pharmacist was important in participating in the multidisciplinary team in terms of eligibility of patients for treatment, to prepare oncological therapies and in processing the evaluation data.

Inhaled sedation is described to be effective to achieve deep sedation and to reduce sedation and extubation time; it also favours a decrease in troponin levels. Its use is also relevant in patients who do not achieve adequate sedation with conventional sedation. The gases used were isoflurane and sevoflurane.There are clinical practice guidelines developed by different societies: American Society of Anesthesiologists, National Institute for Health and Care Excellence, Spanish Society of Intensive Care Medicine and The American Society of Intensive Care Medicine. They consider inhaled sedation as an alternative in patients with bronchospasm and in patients who are difficult to sedate. Conclusion and relevanceIt can be concluded that the use of inhaled gases reduces the extubation and awakening time in critically ill patients. A reduction in troponin concentration is observed. However, these are not 'hard' variables that demonstrate an important clinical impact.Their use may be of interest in patients with bronchospasm or in those who do not achieve an adequate sedation with conventional high-dose sedatives.

respectively. Demographic variables, men: mean weight 78±11 kg, height 1.69±0.08 m and BMI 27±3 kg/m 2 , women: mean weight 67±12 kg, height 1.52±0.12 m and BMI 30±7 kg/ m 2 ). Eighteen patients (51.43%) were considered LR, receiving basiliximab + mean pre-transplant TAC dose of 10 mg and 17 patients (48.57%) as HR, receiving thymoglobulin. Mean TAC dosing regimen until first monitoring, with a mean time of 2 days: 7.25 mg/12 hours in LR and 6.14 mg/12 hours in HR. Mean total dose of TAC up to first monitoring: 33.47 ±13.42 mg in LR and 19.29±8.03 mg in HR. At first monitoring: LR, mean ConTAC of 22.89±8.04 ng/mL (83.3% >15 ng/mL, 11.11% <10 ng/mL, 5.55% 10-15 ng/mL); HR, mean ConTAC of 14.59±8.87 ng/mL (47.05% >15 ng/mL, 35.3% <10 ng/mL, 17.65% 10-15 ng/mL). Mean number of determinations to reach target level: 3 in LR and HR, with a mean time of 6 days in LR and 7 days in HR. Mean Cr value on transplant day and day +7: 5.9±2.7 mg/dL and 3.48±2.1 mg/dL, with mean ClCr of 10.73±5.14 mL/min and 26.8±19.76 mL/min, respectively. Conclusion and relevance Pharmacokinetic monitoring of TAC is useful in immediate renal transplantation since a high percentage of patients present concentrations outside the target therapeutic range in the first determination. Further studies are needed to optimise the initial TAC dosage in this type of patients.

who initiated the treatment were included. Biodemographic, clinical and pharmacotherapy data was collected from the medical records. Parameters were evaluated at treatment initiation and after 6 months. Clinical response, defined as a reduction in low density lipoprotein (LDL) >30%, was analysed by indication. Results PS accepted 93 of 123 patient requests. Only 72 patients (median age 58 years (37-84), 56% men) were included due to lack of data. Cardiovascular risk factors were: hypertension (47.2%), family history of ischaemic heart disease (40.3%), smoking (38.3%), obesity (15.3%), diabetes (12.5%) and ischaemic heart disease (58.3%). Initial LDL values (mg/dL) were 100-129 (23.6%), 130-159 (34.8%), 160-190 (20.8%), and >190 (20.8%). Frequency of additional lipid lowering drugs were: atorvastatin (40.3%), rosuvastatin (27.8%), fluvastatin (2.8%), pitavastatin (2.8%), statin free (26.4%) and ezetimibe (72.2%). During the study, 41.7% of patients showed statin intolerance and 88.9% reached their maximum tolerated dose. After initiating PCSK9I, 83.3% of patients maintained the same dose of statin, 8.3% reduced the dose, 6.9% stopped taking the medication, 4.3% switched to another statin and 1.4% increased the dose. LDL plasma concentration decreased by more than 50% in 52.1% of patients, by 30-50% in 31.2% of patient and by <30% in 16.7%. of patients. The clinical response in primary HFHe prevention was alirocumab 16.7% versus evolocumab 50%, and in secondary HFHe, alirocumab 68.8% versus evolocumab 83.3%. The clinical response in primary HNF prevention was alirocumab 60% (no evolocumab patient) and in HNF/DM secondary prevention, alirocumab 50% versus evolocumab 100%. Conclusion and relevance We found that 16.7% of our population did not achieve a clinical response; PS may play a relevant role, suggesting treatment cessation in these patients. Evolocumab could be especially effective in HFHe; more studies are needed to confirm this finding.